Position in AZN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,644,420
New position
Shares Held
8,338
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Campbell & CO Investment Adviser LLC holds $29,502,691 across 9 Drug Manufacturers - General names. AZN ranks #6 (5.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
50,560 | $7,046,547 | |
| 2 | LLY |
ELI LILLY & Co
|
7,041 | $6,476,100 | |
| 3 | NVS |
Novartis AG
|
39,646 | $6,055,926 | |
| 4 | AMGN |
Amgen Inc
|
14,110 | $4,964,603 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
29,424 | $1,784,565 | |
| 6 | AZN |
Astrazeneca PLC
This page
|
8,338 | $1,644,420 | |
| 7 | OGN |
Organon & Co.
|
128,309 | $768,570 | |
| 8 | GRFS |
Grifols SA
|
63,848 | $512,060 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,644,420 | 8,338 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||